NSD1 inactivating mutations have been reported to occur at a frequency at 10–13% and correlate with a better prognosis for HNSCC patients (9, 12, 13), especially among patients with HPV-negative laryngeal tumors (9), in analysis of a cohort of patients in which treatment with chemoradiation was common. Here, NSD1 is linked to head and neck squamous cell carcinoma.